Analysis of Factors Influencing the Quality of Bowel Preparation Before Colonoscopy in IBD Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Standard Pre-colonoscopy Bowel Preparation Protocol: This involves standard clinical instructions including a low-residue diet prior to colonoscopy and the administration of bowel cleansing agents (e.g., Polyethylene Glycol) according to the split-dose regimen as per each participating center's routine practice. The timing, dosage, and specific agent used follow existing institutional guidelines.
Study summary
The primary objectives of this project are twofold. On the one hand, it aims to investigate the current status of bowel preparation protocols and their quality in IBD patients undergoing colonoscopy, particularly focusing on the implementation of these protocols across hospitals following the release of the 2023 bowel preparation guidelines. This will further standardize and optimize bowel preparation practices in China. On the other hand, the project seeks to identify and examine various risk factors contributing to poor bowel preparation quality in IBD patients, analyze their correlation with bowel preparation scores, and develop a risk prediction model for failed bowel preparation. This will provide a theoretical foundation for formulating personalized bowel preparation regimens tailored to individual patient conditions in the future.
Eligibility
Primary outcome measure(s)
- adequate bowel preparation rate — The adequate bowel preparation rate can be assessed immediately upon completion of colonoscopy
Proportion of subjects with Boston Bowel Preparation Scale (BBPS) scores ≥ 2 in all bowel segments.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Changhai Hospital | Shanghai | Shanghai Municipality | Recruiting |
More Changhai Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07335705 on ClinicalTrials.gov ↗ ← All trials in China